|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We consider that blastoid NK cell lymphoma is an extremely aggressive subtype of CD56-positive lymphomas, and high-dose chemotherapy with peripheral blood stem cell rescue should be included for the choice of the treatment.
|
10048432 |
1999 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
This study indicates that chromosome aberrations in NK-cell lymphomas are restricted to the CD56+, CD3- and CD5- cell population and that NK-cell lymphomas are indeed derived from mature true NK cells and not from T lymphocytes.
|
10354139 |
1999 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Primary purely cutaneous CD56 + lymphomas have rarely been reported.
|
10583121 |
1999 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We have studied 12 patients of varied ethnic backgrounds with CD56-positive lymphomas in the skin.
|
10328090 |
1999 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The diagnosis of NK cell lymphoma was made on the basis of morphological and immunological characteristics (CD3-CD56+) found on skin biopsy of one of multiple skin nodules which subsequently developed in association with splenomegaly, thrombocytopenia and continuing neutropenia.
|
9869207 |
1998 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also studied the expression of these molecules in 92 other cases of T-cell and natural killer (NK) cell neoplasms; 18 anaplastic large cell lymphomas (ALCLs); 63 CD4+ PTCLs; 10 CD56+ nasal lymphomas; and 1 NK-cell leukemia.
|
9578080 |
1998 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fifty percent of MVLs express CD56, suggesting a role for adhesion molecules in the distribution of this lymphoma.
|
9521469 |
1998 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study we analysed the cytogenetic findings of seven patients with CD56-positive putative NK cell lymphoma/leukaemia.
|
9326190 |
1997 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Five CD3- CD56+ lymphoma patients presenting with nodular lesions were identified among 180 immunophenotyped cutaneous lymphomas.
|
9470917 |
1997 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of NCAM could be regarded as responsible, in part, for the extranodal localization of lymphoma cells; expression of CD56 also might contribute to the definition of a subset of CD30+ lymphomas with distinctive clinicopathologic features.
|
9261474 |
1997 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas.
|
8608237 |
1996 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD2+, CD3-, CD56/NCAM+ malignant lymphoma with TCR beta gene rearrangement: a case report.
|
7485082 |
1995 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of the neural cell adhesion molecule (NCAM) (CD56, NKH-1) is a rare phenomenon in malignant lymphoma.
|
7532919 |
1995 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, EBV may play an etiologic role in these CD56-positive lymphomas.
|
7520016 |
1994 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
This case demonstrated nasal cavity and cutaneous tumor infiltrates consistent with previously described CD3-negative, CD56-positive NK-cell lymphoma of the upper aerodigestive tract.
|
7530849 |
1994 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
NCAM (CD56)-positive malignant lymphoma.
|
7512851 |
1993 |